Dr. Reddy's Laboratories Limited (RDY)
| Market Cap | 9.36B |
| Revenue (ttm) | 2.81B |
| Net Income (ttm) | 309.29M |
| Shares Out | 166.10M |
| EPS (ttm) | 1.86 |
| PE Ratio | 20.86 |
| Forward PE | 20.70 |
| Dividend | $0.36 (0.65%) |
| Ex-Dividend Date | Jul 11, 2022 |
| Volume | 44,654 |
| Open | 56.69 |
| Previous Close | 56.37 |
| Day's Range | 56.29 - 56.80 |
| 52-Week Range | 49.59 - 58.28 |
| Beta | 0.24 |
| Analysts | Buy |
| Price Target | 61.81 (+9.71%) |
| Earnings Date | May 18, 2023 |
About RDY
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the bi... [Read more]
Full Company ProfileFinancial Performance
In 2022, RDY's revenue was 214.39 billion, an increase of 13.00% compared to the previous year's 189.72 billion. Earnings were 23.57 billion, an increase of 36.72%.
Financial numbers in INR Financial StatementsAnalyst Forecast
According to 46 analysts, the average rating for RDY stock is "Buy." The 12-month stock price forecast is $61.81, which is an increase of 9.71% from the latest price.
News
5 Top-Ranked Dividend Stocks to Counter Market Volatility
Dr. Reddys (RDY), Darden Restaurants (DRI), Interpublic Group (IPG), Microchip Technology (MCHP) and Valero Energy (VLO) could be compelling picks amid market volatility.
Coya Therapeutics, Inc. Announces an Agreement with Dr. Reddy's Laboratories, Ltd. to License its proposed biosimilar Abatacept for the Development and Commercialization of COYA 302 for the Treatment of Neurodegenerative Diseases
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing multiple therapeutic platforms intended to enhance Treg fu...
Here's Why Doctor Reddy's (RDY) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
3 Generic Drug Stocks to Watch Amid Macro Headwinds
The impact of macroeconomic headwinds on the Zacks Medical - Generic Drugs industry persists. New product launches provide some respite to AMPH, RDY and TEVA.
Dr. Reddy's Laboratories Announces Agreement to Acquire Mayne Pharma's U.S. Generic Prescription Product Portfolio
HYDERABAD, India & BASEL, Switzerland & PRINCETON, N.J.--(BUSINESS WIRE)---- $RDY #DRREDDY--Dr. Reddy's Laboratories announces agreement to acquire Mayne Pharma's U.S. generic prescription product por...
Why Doctor Reddy's (RDY) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Dr. Reddy's included in Bloomberg Gender-Equality Index for the 6th year in a row and S&P Global's Sustainability Yearbook for the 3rd year
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #Bloomberg--Dr. Reddy's Laboratories Ltd announced major back-to-back recognitions in gender equality and sustainability.
The 3 Most Undervalued Stocks in India for Your February Buy List
The Indian markets have been in focus with the recent Hindenburg Research report on the Adani Group. The report alleges that the group has pulled off the “largest con in corporate history.
Dr. Reddy's (RDY) Q3 Earnings & Revenues Beat Estimates
Dr. Reddy's (RDY) beat earnings and revenues in the fiscal third quarter, driven by growth in the United States and Russian markets.
Dr. Reddy's Laboratories announces the launch of Difluprednate Ophthalmic Emulsion 0.05% in the U.S. Market
HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. R...
Dr. Reddy's successfully completes full set of clinical studies of its rituximab biosimilar for filing in the U.S., Europe
HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; hereafter referred to as “Dr. Reddy's”), a global pharmaceutical company, an...
New Strong Buy Stocks for January 10th
STNE, JD, VSH, MOMO and RDY have been added to the Zacks Rank #1 (Strong Buy) List on January 10 , 2023.
5 Best Emerging Markets Stocks to Buy for 2023
Here are five emerging market stocks, JD, SGML, RDY, MMYT and CPNG that are expected to gain enormously in 2023, capitalizing on their growth prospects.
Dr. Reddy's Successfully Completes Phase 1 Study of DRL_TC, a Proposed Biosimilar of Tocilizumab
HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; hereafter referred to as “Dr. Reddy's”), a global pharmaceutical company, an...
3 Generic Drug Stocks to Watch Amid Inflation Pressures
The impact of inflationary headwinds and pricing pressure on the Zacks Medical - Generic Drugs industry persists. New product launches provide some respite to AMPH, RDY and SLGL.
New Strong Buy Stocks for November 17th
PSX, DCP, RDY, PDFS and CRZBY have been added to the Zacks Rank #1 (Strong Buy) List on November 17, 2022.
Doctor Reddy's (RDY) is a Top-Ranked Momentum Stock: Should You Buy?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Dr. Reddy's (RDY) Earnings & Revenues Trump Estimates in Q2
Dr. Reddy's (RDY) earnings and sales beat estimates in second-quarter fiscal 2023.
World Economic Forum Recognises Dr. Reddy's Hyderabad Factory as Part of its Global Lighthouse Network
HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)---- $RDY #4IR--World Economic Forum recognises Dr. Reddy's Hyderabad factory as part of its Global Lighthouse Network.
Doctor Reddy's (RDY) is a Top-Ranked Value Stock: Should You Buy?
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
3 Generic Drug Stocks to Watch Amid Continued Pricing Pressure
The impact of COVID-19 and pricing pressure on the Zacks Medical - Generic Drugs industry persists. New product launches provide some respite to TEVA, RDY and SLGL.
Dr. Reddy's Laboratories Announces the Launch of Lenalidomide Capsules in the U.S. With Two of Six Strengths Eligible for First-to-market, 180-day Exclusivity
HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)---- $RDY #Affordablemedicines--Dr. Reddy's Laboratories Ltd. today announced the launch, in the U.S. market, of Lenalidomide Capsules.
Plaintiff in first Zantac lawsuit set for trial drops case
The plaintiff in the first lawsuit over the heartburn drug Zantac scheduled to go to trial has agreed to drop his case, according to his attorney and drugmakers named as defendants.
Doctor Reddy's (RDY) is a Top-Ranked Growth Stock: Should You Buy?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Dr. Reddy's (RDY) Q1 Earnings Increase Y/Y, Sales Increase
Dr. Reddy's (RDY) earnings and sales increase year over year in first-quarter fiscal 2023.